RBD1016

DRUG5 trials

Sponsors

Ribocure Pharmaceuticals AB, Suzhou Ribo Life Science Co. Ltd.

Conditions

Chronic Hepatitis BChronic Hepatitis DChronic Hepatitis bChronic hepatitis D virus infectionHealthy Volunteers

Phase 1

A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016

CompletedNCT04685564

Suzhou Ribo Life Science Co. Ltd.Healthy Volunteers

Start: 2021-02-05End: 2021-11-02Updated: 2022-04-26

A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

CompletedNCT05017116

Suzhou Ribo Life Science Co. Ltd.Chronic Hepatitis B

Start: 2021-08-09End: 2023-10-25Updated: 2024-12-06

Phase 2

A Study of RBD1016 in CHB Participants

CompletedNCT05961098

Suzhou Ribo Life Science Co. Ltd.Chronic Hepatitis b

Start: 2023-10-11End: 2025-10-15Updated: 2025-12-09

A phase 2a, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of RBD1016 in participants with chronic hepatitis D virus infection, including a randomized, single-blinded, placebo-controlled exploratory part

Active, not recruitingCTIS2023-509007-33-00

Ribocure Pharmaceuticals ABChronic hepatitis D virus infection

Start: 2024-08-21Target: 15Updated: 2025-12-19

Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D

Active, not recruitingNCT06649266

Ribocure Pharmaceuticals ABChronic Hepatitis D

Start: 2024-08-21End: 2027-08-01Updated: 2026-02-03